Filtered By:
Condition: Ischemic Stroke
Drug: Actos

This page shows you your search results in order of relevance. This is page number 5.

Order by Relevance | Date

Total 67 results found since Jan 2013.

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
New England Journal of Medicine,Volume 375, Issue 7, Page 702-704, August 2016.
Source: New England Journal of Medicine - August 16, 2016 Category: Internal Medicine Source Type: research

Pioglitazone and risk for bone fracture: safety data from a randomized clinical trial - Viscoli CM, Inzucchi SE, Young LH, Insogna KL, Conwit R, Furie KL, Gorman M, Kelly MA, Lovejoy AM, Kernan WN.
CONTEXT: Pioglitazone reduces cardiovascular risk in non-diabetic patients after an ischemic stroke or transient ischemic attack (TIA) but is associated with increased risk for bone fracture. OBJECTIVE: To characterize fractures associated with pio...
Source: SafetyLit - December 17, 2016 Category: Global & Universal Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news

Leptin, cardiovascular diseases and type 2 diabetes mellitus.
Abstract Leptin, an adipokine that is implicated in the control of food intake via appetite suppression, may also stimulate oxidative stress, inflammation, thrombosis, arterial stiffness, angiogenesis and atherogenesis. These leptin-induced effects may predispose to the development of cardiovascular diseases. In the present review we discuss the evidence linking leptin levels with the presence, severity and/or prognosis of both coronary artery disease and non-cardiac vascular diseases such as stroke, carotid artery disease, peripheral artery disease (PAD) and abdominal aortic aneurysms (AAA) as well as with chroni...
Source: Acta Pharmacologica Sinica - June 7, 2018 Category: Drugs & Pharmacology Authors: Katsiki N, Mikhailidis DP, Banach M Tags: Acta Pharmacol Sin Source Type: research

Effect of pioglitazone in acute ischemic stroke patients with diabetes mellitus: a nested case –control study
Pioglitazone is an oral antidiabetic drug with multiple pleiotropic actions. Recent clinical trials have demonstrated that treatment with pioglitazone reduces cardiovascular risk in patients who have had an is...
Source: Cardiovascular Diabetology - May 31, 2019 Category: Cardiology Authors: Min-Hee Woo, Hye Sun Lee and Jinkwon Kim Tags: Original investigation Source Type: research

Activation of The Metabolic Master Regulator PPAR γ - A Potential PIOneering Therapy for Pulmonary Arterial Hypertension.
The objective is a data-driven approach to set the preclinical and clinical study record straight. The convincing recent clinical trial data on the lack of significant toxicity in high risk populations justify the timely conduction of clinical studies in order to achieve "repurposing" or "repositioning" of pioglitazone for the treatment of clinical PAH. PMID: 31577451 [PubMed - as supplied by publisher]
Source: Am J Respir Cell Mol... - October 1, 2019 Category: Respiratory Medicine Authors: Hansmann G, Calvier L, Risbano MG, Chan SY Tags: Am J Respir Cell Mol Biol Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Pioglitazone Use Linked to Reduced Dementia Risk in T2DM
THURSDAY, Feb. 16, 2023 -- For patients with diabetes mellitus (DM), pioglitazone use is associated with a reduced risk for dementia, especially in those with a history of ischemic heart disease or stroke, according to a study published online Feb....
Source: Drugs.com - Pharma News - February 16, 2023 Category: Pharmaceuticals Source Type: news